sharon sanders
Editor-in-Chief & President
【Wuhan Pneumonia】 Latest announcement Yuan Guoyong's rare disease "nemesis" is mainly used for lung lung cocktail therapy
4 hours ago
The Department of Microbiology of the University of Hong Kong and the Hong Kong Public Hospital launched the first study on mixed drug treatment of patients with mild to moderate Wuhan pneumonia, and found the use of Beta interferon, lopinavir / ritonavir and ribavir The combination therapy of Velin, compared with the use of lopinavir / ritonavir alone, can suppress the virus for 5 days, resolve the symptoms for 4 days, and discharge to hospital in 5.5 days.
Yuan Guoyong, Chair Professor of the Department of Microbiology at the University of Hong Kong, said that studies have shown that treatment of mild to moderate patients with mixed drugs within 7 days after the onset of disease can quickly suppress the amount of virus, reduce the time of virus transmission and the risk of infection by medical staff.
The patient's average condition at 52 years old was mild to moderate
The study, published in the international medical journal "Needle Needle", involved 127 confirmed patients with Wuhan pneumonia who were admitted to six public hospitals from early February to mid-March. They were 52 years old on average and had mild to moderate illness. Patients were randomized to use a combination of drugs, namely Beta interferon, lopinavir / ritonavir and ribavirin, or a control group that used only lopinavir / ritonavir.
86 patients used the mixed drug for 14 days, with lopinavir / ritonavir and ribavirin 12 hours apart daily, and injected up to 3 doses of Beta interferon every other day; the remaining 41 patients served as a control group , Only use lopinavir / ritonavir every 12 hours.
All patients take the medicine on average 5 days after the onset of the disease. If necessary, they will use steroids, antibiotics and ventilators. Researchers monitor the patient's clinical symptoms, nasopharyngeal swabs, deep throat saliva and other sample tests to understand the changes in viral volume.
On average, 9 days in a group of mixed drugs
It was found that after the patients began to use the mixed drugs, the virus was effectively suppressed within an average of 7 days, and the virus could not be detected by the nasopharyngeal swab test; it took an average of 12 days to suppress the virus compared with the control group, and the average was 5 days faster.
In a group of mixed drugs, the symptoms resolved on average only 4 days, and the average hospitalization was 9 days; while the control group patients took 8 days to resolve the symptoms, and the average hospitalization was 14.5 days.
Studies have shown that the sooner patients receive mixed drug treatment, the better the effect. 52 patients used the mixed drug within 7 days after the onset of disease. The clinical treatment and the effect of reducing the amount of virus were better than those of the control group who also took the drug within 7 days after the onset of the disease. However, 34 patients who took the mixed drugs (excluding interferon) 7 days or more after the onset of the disease had similar therapeutic effects as the 17 control patients who also took the drugs 7 days or more after the onset of the disease.
Study on Beta interferon as a drug for the treatment of Wufei backbone
The study pointed out that Beta interferon is the main element in mixed drug therapy, which can strengthen the body's ability to attack Wuhan pneumonia virus and respond to viral infections. Future Phase III clinical studies can further determine whether Beta interferon is the backbone of Wuhan pneumonia drug.
In terms of side effects, the two groups of patients were in a similar situation. 48% of the patients who used mixed drugs and 49% of the patients in the control group had side effects, mainly diarrhea, fever and runny nose. Only one patient in the control group had severe liver problems and did not continue to take medication.
Yuan Guoyong said that although the study confirmed the efficacy of mixed drugs in the treatment of patients with mild to moderate disease, a third-phase clinical study is still required to determine the effect of treating severe patients and the effect of Beta interferon alone.
Treatment with mixed drugs effectively reduces drug resistance
In 2003, lopinavir / ritonavir and ribavirin were used to treat SARS patients, which can significantly reduce the risk of respiratory failure and death. Beta interferon, originally used to treat multiple sclerosis, can reduce the number of Middle East Respiratory Syndrome coronavirus in animal experiments. Influenza is similar to Wuhan pneumonia. The amount of virus in the human body is higher when the symptoms appear. The treatment effect of flu with mixed drugs is better than that of a single drug, and it can also reduce drug resistance. So the researchers hypothesized that the same drug was used to treat Wuhan pneumonia.
https://hk.video.appledaily.com/loca...SFZUCMKTME57A/
4 hours ago
The Department of Microbiology of the University of Hong Kong and the Hong Kong Public Hospital launched the first study on mixed drug treatment of patients with mild to moderate Wuhan pneumonia, and found the use of Beta interferon, lopinavir / ritonavir and ribavir The combination therapy of Velin, compared with the use of lopinavir / ritonavir alone, can suppress the virus for 5 days, resolve the symptoms for 4 days, and discharge to hospital in 5.5 days.
Yuan Guoyong, Chair Professor of the Department of Microbiology at the University of Hong Kong, said that studies have shown that treatment of mild to moderate patients with mixed drugs within 7 days after the onset of disease can quickly suppress the amount of virus, reduce the time of virus transmission and the risk of infection by medical staff.
The patient's average condition at 52 years old was mild to moderate
The study, published in the international medical journal "Needle Needle", involved 127 confirmed patients with Wuhan pneumonia who were admitted to six public hospitals from early February to mid-March. They were 52 years old on average and had mild to moderate illness. Patients were randomized to use a combination of drugs, namely Beta interferon, lopinavir / ritonavir and ribavirin, or a control group that used only lopinavir / ritonavir.
86 patients used the mixed drug for 14 days, with lopinavir / ritonavir and ribavirin 12 hours apart daily, and injected up to 3 doses of Beta interferon every other day; the remaining 41 patients served as a control group , Only use lopinavir / ritonavir every 12 hours.
All patients take the medicine on average 5 days after the onset of the disease. If necessary, they will use steroids, antibiotics and ventilators. Researchers monitor the patient's clinical symptoms, nasopharyngeal swabs, deep throat saliva and other sample tests to understand the changes in viral volume.
On average, 9 days in a group of mixed drugs
It was found that after the patients began to use the mixed drugs, the virus was effectively suppressed within an average of 7 days, and the virus could not be detected by the nasopharyngeal swab test; it took an average of 12 days to suppress the virus compared with the control group, and the average was 5 days faster.
In a group of mixed drugs, the symptoms resolved on average only 4 days, and the average hospitalization was 9 days; while the control group patients took 8 days to resolve the symptoms, and the average hospitalization was 14.5 days.
Studies have shown that the sooner patients receive mixed drug treatment, the better the effect. 52 patients used the mixed drug within 7 days after the onset of disease. The clinical treatment and the effect of reducing the amount of virus were better than those of the control group who also took the drug within 7 days after the onset of the disease. However, 34 patients who took the mixed drugs (excluding interferon) 7 days or more after the onset of the disease had similar therapeutic effects as the 17 control patients who also took the drugs 7 days or more after the onset of the disease.
Study on Beta interferon as a drug for the treatment of Wufei backbone
The study pointed out that Beta interferon is the main element in mixed drug therapy, which can strengthen the body's ability to attack Wuhan pneumonia virus and respond to viral infections. Future Phase III clinical studies can further determine whether Beta interferon is the backbone of Wuhan pneumonia drug.
In terms of side effects, the two groups of patients were in a similar situation. 48% of the patients who used mixed drugs and 49% of the patients in the control group had side effects, mainly diarrhea, fever and runny nose. Only one patient in the control group had severe liver problems and did not continue to take medication.
Yuan Guoyong said that although the study confirmed the efficacy of mixed drugs in the treatment of patients with mild to moderate disease, a third-phase clinical study is still required to determine the effect of treating severe patients and the effect of Beta interferon alone.
Treatment with mixed drugs effectively reduces drug resistance
In 2003, lopinavir / ritonavir and ribavirin were used to treat SARS patients, which can significantly reduce the risk of respiratory failure and death. Beta interferon, originally used to treat multiple sclerosis, can reduce the number of Middle East Respiratory Syndrome coronavirus in animal experiments. Influenza is similar to Wuhan pneumonia. The amount of virus in the human body is higher when the symptoms appear. The treatment effect of flu with mixed drugs is better than that of a single drug, and it can also reduce drug resistance. So the researchers hypothesized that the same drug was used to treat Wuhan pneumonia.
https://hk.video.appledaily.com/loca...SFZUCMKTME57A/